TTI-101

Phase 2Small molecule

TTvardi Therapeutics, Incorporated

TTI-101 is one of 206 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

205

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Breast CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

Idiopathic Pulmonary FibrosisActive, not recruiting

Squamous Cell CarcinomaActive, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 1

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Hepatocellular CarcinomaPhase 1/Phase 2

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 1/Phase 2

Active, not recruiting

Idiopathic Pulmonary FibrosisPhase 2

Active, not recruiting

Squamous Cell CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

TTI-101

TTvardi Therapeutics, Incorporated

Phase 2

1 3

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 4

Zolymbus

AbbVie

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 7

Acupan

YYonsei University

Preclinical

1 8

Paracetamol

GSK

Preclinical

1 9

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 10

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Hepatocellular Carcinoma

NCT05440708

Q2 2029

Phase 1Active, not recruiting

Pancreatic Ductal Adenocarcinoma

NCT06141031

Clinical

Trials by Indication[1]

Idiopathic Pulmonary Fibrosis1 trial

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Completed·TTvardi Therapeutics, Incorporated·Phase 2·NCT05671835·100 enrolled

Breast Cancer1 trial

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Terminated·TTvardi Therapeutics, Incorporated·Phase 1·NCT05384119·6 enrolled

Squamous Cell Carcinoma1 trial

Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT05845307

Advanced Cancers1 trial

Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers

Completed·TTvardi Therapeutics, Incorporated·Phase 1·NCT03195699·64 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT05668949

2 more indications

Hepatocellular Carcinoma1 trial

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Recruiting·TTvardi Therapeutics, Incorporated·Phase 1/2·NCT05440708·178 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

Active, not recruiting·WWashington University School of Medicine·Phase 1·NCT06141031·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for TTI-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TTI-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TTI-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tvardi Therapeutics, Incorporated company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTvardi Therapeutics, Incorporated

TTI-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2029

Trials by Indication[1]

Idiopathic Pulmonary Fibrosis1 trial

Breast Cancer1 trial

Squamous Cell Carcinoma1 trial

Advanced Cancers1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Hepatocellular Carcinoma1 trial

Pancreatic Ductal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News